

## Levofloxacin

|                                      |  |
|--------------------------------------|--|
| <b>Form</b>                          | 500mg in 100mL bottle  |
| <b>Reconstitution</b>                | Already in solution  |
| <b>Compatibility &amp; Stability</b> | N/A  |
| <b>Administration</b>                | <p>Only clear solutions, free from particles, should be used. Solution may be greenish-yellow in colour.</p> <p><b>IV Infusion</b><br/>Administer 250mg over at least 30 minutes and 500mg over at least 60 minutes.</p> <p>Perforated bottles/bags should be used immediately (within 3 hours of perforation of rubber stopper/bag).</p>  |
| <b>Monitoring</b>                    | Monitor blood pressure during infusion. If a noticeable drop in blood pressure occurs, the infusion must be stopped immediately.   |
| <b>Additional Information</b>        | <ul style="list-style-type: none"> <li>Levofloxacin has excellent bioavailability. Consider oral route from the onset, or a rapid IV to po switch as appropriate. See CUH Antimicrobial Guidelines on <a href="#">Microguide</a> for further information.</li> <li>Fluoroquinolones (FQ) are associated with serious adverse effects affecting muscles, tendons, bones and the nervous system. See CUH Antimicrobial Guidelines on <a href="#">Microguide</a> for further information <a href="https://www.hpra.ie/docs/default-source/publications-forms/newsletters/hpra-drug-safety-newsletter-edition-91.pdf?sfvrsn=7">https://www.hpra.ie/docs/default-source/publications-forms/newsletters/hpra-drug-safety-newsletter-edition-91.pdf?sfvrsn=7</a></li> </ul> |

**Information provided relates to Tavanic® manufactured by Sanofi Aventis, and Levofloxacin by Fresenius Kabi.**